Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 243

Results For "NDA"

4846 News Found

Govt.  setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
News | March 04, 2024

Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS

Launch of Indian public health standards for Ayush healthcare facilities


USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval | March 02, 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently


Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
Drug Approval | March 02, 2024

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024


Cabinet approves post of director for National Institute for One Health
Policy | March 02, 2024

Cabinet approves post of director for National Institute for One Health

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness


Briefs: Eugia Pharma Specialities and Eugia SEZ
News | March 01, 2024

Briefs: Eugia Pharma Specialities and Eugia SEZ

Eugia Pharma Specialities restarts production at terminally sterilized product lines


Pfizer Oncology hosts innovation day
News | March 01, 2024

Pfizer Oncology hosts innovation day

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth


Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less
News | February 29, 2024

Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less

Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals


Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
Clinical Trials | February 28, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis